Recent Quotes (30 days)

You have no recent quotes
chg | %

AEterna Zentaris Inc. (USA)  

(Public, NASDAQ:AEZS)   Watch this stock  
Find more results for AEZS
-0.02 (-0.95%)
After Hours: 2.01 -0.01 (-0.52%)
Oct 19, 4:05PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.92 - 2.07
52 week 0.78 - 5.59
Open 2.03
Vol / Avg. 370,291.00/556,020.00
Mkt cap 32.56M
P/E     -
Div/yield     -
EPS -1.81
Shares 16.21M
Beta 1.12
Inst. own 110%

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -1049.38% -2739.74%
Operating margin -2748.56% -3235.57%
EBITD margin - -3204.83%
Return on average assets -38.90% -60.03%
Return on average equity -207.82% -179.39%
Employees 56 -
CDP Score - -


315 Sigma Dr Ste 302D
SUMMERVILLE, SC 29486-7790
United States - Map
+1-843-9003223 (Phone)
+1-418-9489191 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

Officers and directors

Carolyn Egbert Independent Chairman of the Board
Bio & Compensation  - Reuters
Michael Ward President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Jeffrey A. Whitnell CPA Interim Chief Financial Officer
Age: 58
Bio & Compensation  - Reuters
Richard Sachse M.D. Ph.D. Senior Vice President, Chief Scientific Officer, Chief Medical Officer
Bio & Compensation  - Reuters
Jude Dinges Chief Commercial Officer, Senior Vice President
Bio & Compensation  - Reuters
Eckhard G. Gunther Ph.D. Vice President - Alliance Management
Bio & Compensation  - Reuters
Michael Teifel Vice President - Non-Clinical Sciences
Bio & Compensation  - Reuters
John W. Sharkey Ph.D. Business Development Consultant
Age: 60
Bio & Compensation  - Reuters
Philip Allen Theodore Corporate Secretary
Age: 62
Bio & Compensation  - Reuters
David A. Dodd Director
Age: 65
Bio & Compensation  - Reuters